PHILADELPHIA, March 12 /PRNewswire/ -- ERT, a leading provider of centralized ECG and eClinical technology, ePRO, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will be showcasing its portfolio of products and services on Booth #1253/1254 at the 21st Annual DIA Euromeeting, 23-25 March 2009 in Berlin, Germany. ERT is also inviting attendees to three speaking sessions, which will discuss the impact of technology and standards on drug delivery.
Following a successful company rebranding exercise, ERT has unveiled four new sub-brands of its industry-leading products and services, including ERT Cardiac Safety Solutions, ERT EDC Solutions, ERT ePRO Solutions, and ERT Clinical Research Consulting Group. ERT representatives will be on booth at the DIA Euromeeting to discuss the Company's latest innovations, as well as the latest advancements within the industry.
In addition, ERT will be taking part in three presentations at the Euromeeting under the conference track, The Impact of Technology and Standards on Drug Development: Now Better, Safer and Faster. The first talk, entitled "The Loose Ends in EDC and How to Address Them," will be held on 24 March between 4:00 pm - 5:30 pm. The second session - "A Look into the Future: What is on the Horizon After We Have Managed EDC Properly?" - will be held from 9:00 am to 10:30 am, on 25 March. The final session will also be held on 25 March between 2:00 pm - 3:30 pm entitled "CDISC end-to-end: To What Extent Do the CDISC Standards Achieve Information System Independence?"
DIA's 21st Annual Euromeeting attracts more than 3,000 professionals from over 50 countries. It brings together representatives from the biopharmaceutical industry, contract service organizations, academic research centers, regulatory agencies, health ministries, patients' organizations and trade associations. More than 240 exhibitors will be taking part at the DIA meeting, which will also feature more than 125 sessions and 21 preconference tutorials focusing on issues affecting global drug discovery and development.
ERT is a leading provider of technology and services to the biopharmaceutical and medical device industries around the world. The four key areas of ERT products and services are all enabled by the Company's innovative technology platform - EXPERT(TM). EXPERT(TM) is a robust, secure, and validated clinical-research workflow-processing system that powers centralized electronic data collection, data management, and information exchange.
For further information about ERT's clinical trial solutions please visit Booth #1253/1254 at DIA 21st Annual Euromeeting in Berlin. Alternatively, please email email@example.com, call +1 866 538 2808 or visit www.ert.com.
Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.) (www.ert.com) is a provider of technology and services to the biopharmaceutical and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including, but not limited to, 2009 financial guidance, involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Copyright©2009 PR Newswire.
All rights reserved